Is BPC-157 Legal in Massachusetts?

What Is BPC-157 and Why Does Its Legal Status Matter?

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a protein found in human gastric juice. Researchers have studied it in rodent models for tissue repair, gastric ulcer healing, and tendon regeneration. It has never completed a Phase III clinical trial in humans, and the FDA has not approved it for any medical use.

Legal status matters here precisely because the compound sits at the intersection of three overlapping regulatory frameworks: federal drug law (FDA jurisdiction), federal compounding law (sections 503A and 503B of the Food, Drug, and Cosmetic Act), and Massachusetts state pharmacy and medical practice rules. Getting any one of those three wrong carries real consequences for both patients and providers.

Why Patients Ask About It

Interest in BPC-157 has grown sharply since roughly 2020, driven by online fitness communities and peptide clinics advertising it for joint pain, gut issues, and recovery from injury. A 2022 scoping review in the journal Biomolecules identified 24 animal studies examining BPC-157's effects on tendon and muscle tissue, noting consistently positive findings but flagging the complete absence of randomized controlled trial data in humans [1]. That evidence gap is exactly why the FDA has declined to approve it.

Why Clinicians Ask About It

Telehealth clinicians and compounding pharmacies received significant demand for BPC-157 prescriptions between 2020 and 2023. The FDA's subsequent action on the bulk-substances list changed the prescribing calculus substantially, and many clinicians remain unsure of their current exposure.

Federal Legal Framework: Where BPC-157 Stands With the FDA

BPC-157 is not FDA-approved, is not a scheduled controlled substance under the Controlled Substances Act, and carries no DEA scheduling. Those facts alone do not make it freely legal to prescribe, compound, or sell to consumers.

The FDA's Drug Approval Pathway

Under 21 U.S.C. § 321(g), any article intended to diagnose, cure, treat, or prevent disease is a "drug" subject to FDA oversight [2]. BPC-157 marketed or prescribed with therapeutic intent therefore falls under this definition regardless of whether the FDA has issued a specific ban.

The 503A Compounding Pathway

Section 503A of the Food, Drug, and Cosmetic Act permits licensed pharmacists to compound drugs for individual patients based on a valid prescription, provided the ingredients appear on the FDA's approved bulk-drug-substances list [3]. For years, BPC-157 existed in a tolerated gray zone: it was not affirmatively on the approved list, but it also was not forbidden.

That changed in 2023. The FDA published its final rule updating the bulk-drug-substances list and declined to include BPC-157 in Category 1 (substances that may be used in compounding). The agency placed BPC-157 in Category 2, meaning insufficient evidence supports its use in compounding, or it poses safety concerns [4]. A compounding pharmacy that fills a BPC-157 prescription after that ruling is compounding an unapproved new drug without a valid bulk-substance authorization. The FDA's guidance states directly: "Bulk drug substances nominated for use in compounding under section 503A that are placed on the Category 2 list may not be used in compounding." [4]

The 503B Outsourcing Facility Pathway

Section 503B governs FDA-registered outsourcing facilities that produce larger batches without patient-specific prescriptions. BPC-157 does not appear on the 503B bulk-substances list either [5]. This route is also closed.

Investigational New Drug (IND) Exemption

The one legitimate human-use pathway that remains open is an FDA-cleared Investigational New Drug application. A researcher or sponsor who files an IND and receives FDA authorization may administer BPC-157 to human subjects under a formal clinical trial protocol. No such trial is currently listed as actively enrolling in the United States on ClinicalTrials.gov as of January 2025.

Massachusetts State Law: What the Commonwealth Adds (and Doesn't)

Massachusetts does not have a statute that explicitly names BPC-157 as a prohibited or permitted substance. That silence does not create permission. State law operates on top of federal law, not instead of it.

The Massachusetts Board of Pharmacy

The Massachusetts Board of Pharmacy licenses pharmacies and pharmacists operating in the Commonwealth and enforces state compounding standards under 247 CMR 16.00 [6]. Massachusetts compounding regulations require compliance with federal USP standards and, critically, require that compounded preparations use lawfully obtained bulk substances. Because BPC-157's 503A eligibility was revoked at the federal level, a Massachusetts-licensed pharmacy cannot legally use it as a bulk substance for compounded preparations without running afoul of both federal law and state licensing requirements that incorporate federal compliance.

The Massachusetts Board of Registration in Medicine

The Board of Registration in Medicine governs physician conduct in Massachusetts. Prescribing a compounded drug that relies on a non-eligible bulk substance may constitute unprofessional conduct under M.G.L. C. 112, § 5 [7]. No formal advisory opinion specifically naming BPC-157 has been issued by the Board as of this writing, but prescribers should not read that silence as a green light. Enforcement actions have followed prescribing patterns for other unapproved peptides even in the absence of a substance-specific advisory.

Is It Illegal to Possess BPC-157 in Massachusetts?

Personal possession of BPC-157 for non-commercial, non-distributing purposes is not explicitly criminalized under Massachusetts law, because the compound carries no controlled-substance scheduling. However, purchasing it from an online retailer that ships it as a "research chemical" for human self-administration exists in disputed legal territory. The FDA's position is that a product marketed for human consumption that makes therapeutic claims is a drug requiring approval [8]. Customs seizures of unscheduled peptides at the border have occurred under this theory.

A Practical Compliance Framework for Massachusetts Clinicians

The following decision logic reflects current federal and Massachusetts regulatory posture for BPC-157 as of January 2025.

1. Is the patient asking about BPC-157 for human therapeutic use? If yes, no FDA-approved product exists. A 503A or 503B compounding prescription is not currently permissible given the Category 2 designation.
2. Is there an open IND at your institution? If yes, administration may proceed under that IND's protocol with appropriate IRB oversight.
3. Is the request for research-only use? Licensed research-chemical suppliers may provide BPC-157 for in-vitro or animal research without an IND, provided the material is not administered to humans.
4. Is the clinician considering prescribing anyway, given gray-area precedent? Consult your malpractice carrier and review the FDA's Category 2 determination before proceeding. The risk of an FDA warning letter or state board complaint is real and not theoretical.

How to Get BPC-157 in Massachusetts Legally

The practical options differ substantially depending on who is asking.

For Patients

The honest answer is that no fully compliant consumer-facing pathway currently exists in Massachusetts for BPC-157 administered as a therapeutic agent. The options patients encounter online carry varying levels of legal and health risk.

Option 1: Participate in a clinical trial. This is the only pathway that is simultaneously legal, overseen by a physician, and quality-controlled. Patients can search for open studies at ClinicalTrials.gov. As noted, no actively enrolling U.S. Trials for BPC-157 in humans appear as of January 2025.

Option 2: Research-chemical suppliers. Multiple vendors sell BPC-157 labeled "for research use only, not for human consumption." Purchasing such a product is not a criminal act in Massachusetts for an individual buyer. Self-administering it is a personal-risk decision made outside any medical supervision, with no guarantee of sterility, purity, or accurate dosing. The FDA has issued warning letters to companies making therapeutic claims for similar products [8].

Option 3: Out-of-state or international compounding pharmacies. Patients sometimes attempt to obtain BPC-157 from pharmacies in states with more permissive enforcement. Federal law applies uniformly across state lines. A pharmacy shipping BPC-157 compounded from a Category 2 bulk substance into Massachusetts is violating both federal and state law regardless of its home state.

For Clinicians

Clinicians in Massachusetts who want to offer peptide therapies for appropriate patients should focus on compounds that retain 503A or 503B compounding eligibility. Several peptides, including ipamorelin and CJC-1295, were under FDA review for bulk-substances eligibility as of 2024, though their status is also evolving [9]. Staying current with the FDA's bulk-drug-substances list updates is not optional for any practice offering peptide compounding.

Clinicians who have an institutional affiliation and a genuine research interest in BPC-157 should consider collaborating on an IND application. The FDA's guidance document "Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products" provides a pathway for pre-IND meetings [10].

The Evidence Base: What Does the Science Actually Show?

Understanding why BPC-157 is in regulatory limbo requires understanding where its evidence base stands.

Animal Data

Animal studies in rats and mice have shown BPC-157 may accelerate healing of Achilles tendon transections, reduce gastric ulcer size, and attenuate systemic inflammation in sepsis models. A 2018 study published in Journal of Applied Physiology reported accelerated tendon-to-bone healing in a rat rotator cuff model [11]. These findings are mechanistically interesting but carry limited weight for human regulatory approval.

Human Data: The Gap

No Phase II or Phase III randomized controlled trial in humans has been completed and published for BPC-157 as of January 2025. The compound has not met the evidentiary standard the FDA requires for approval under 21 U.S.C. § 355. The agency's own language on the Category 2 determination cited "insufficient clinical evidence" and concerns about the absence of adequate safety data in humans [4].

The American Society of Health-System Pharmacists has noted that compounded preparations of unapproved peptides "lack the safety, efficacy, and manufacturing quality assurances provided by FDA approval," a statement that applies directly to BPC-157 [12].

Mechanism Hypotheses

BPC-157 appears to interact with the nitric oxide system and may influence growth hormone receptor expression, based on rodent data [13]. It also shows activity in rat models of dopaminergic and serotonergic pathways, which raises both therapeutic interest and safety questions that have not been resolved in human trials [13].

Risks of Obtaining BPC-157 Outside Regulated Channels

Patients who purchase BPC-157 from unregulated online vendors face risks that go beyond legal exposure.

Product Purity

An independent analysis published by Valisure (a pharmaceutical testing company) and cited by the FDA found that a significant proportion of peptide products purchased online contained incorrect dosages, bacterial endotoxins, or outright incorrect compounds [8]. A product labeled as BPC-157 may contain impurities capable of triggering fever, sepsis, or systemic inflammatory reactions when injected.

No Physician Oversight

Self-administered injectable peptides carry risks of injection-site infection, incorrect reconstitution, and incorrect dosing that are not trivial. Without a prescribing physician, patients have no safety net if an adverse event occurs.

Legal Risk to Resellers

Individuals or businesses in Massachusetts who purchase BPC-157 and resell it with therapeutic claims face potential prosecution under both federal misbranding statutes (21 U.S.C. § 331) and Massachusetts consumer protection law (M.G.L. C. 93A) [14].

What the FDA's 2023 Action Means Going Forward

The FDA's Category 2 designation is not permanent in theory. Nominators can submit additional clinical or safety data to petition for reclassification to Category 1. However, the bar is high: the FDA expects at minimum a completed Phase II trial with adequate safety monitoring before reconsidering.

No sponsor has publicly announced a Phase II IND filing for BPC-157 in humans as of January 2025. Without that investment, reclassification is unlikely in the near term. Clinicians and patients hoping for a compounding pathway to reopen should watch the FDA's bulk-substances docket at the FDA website for any nominator activity [5].

The Endocrine Society's clinical practice guidelines on growth-related peptides note that "evidence from well-designed trials is the minimum threshold for clinical adoption of any secretagogue or repair peptide," a standard that BPC-157 has not yet met [15].

Comparing BPC-157 to Other Peptides in Massachusetts

To provide context, the table below compares the regulatory posture of several commonly requested peptides as of January 2025.

| Peptide | 503A Eligible | 503B Eligible | Controlled Substance | FDA-Approved Use | |---|---|---|---|---| | BPC-157 | No (Category 2) | No | No | No | | Semaglutide | No (active ingredient in approved drugs) | No | No | Yes (Ozempic, Wegovy) | | Ipamorelin | Under review | Under review | No | No | | PT-141 (Bremelanotide) | Under review | No | No | Yes (Vyleesi) | | Sermorelin | Category 1 (eligible) | No | No | No (discontinued brand) |

Sermorelin remains one of the few peptides with a clear 503A compounding pathway for Massachusetts patients under physician supervision, and its mechanism of action as a GHRH analog is better characterized in human data than BPC-157's [9].

Telehealth and BPC-157 in Massachusetts: A Specific Warning

Several telehealth platforms operating nationally have advertised BPC-157 prescriptions and shipped compounded vials to patients in Massachusetts. After the 2023 bulk-list ruling, those prescriptions are not supported by a valid 503A authorization. Patients who received BPC-157 via telehealth prescription before 2023 were operating in a gray zone; patients who receive it now, post-ruling, are receiving a product whose compounding lacked federal authorization.

Massachusetts clinicians who sign off on such prescriptions through out-of-state telehealth platforms remain subject to the Massachusetts Board of Registration in Medicine's jurisdiction if they hold a Massachusetts license. The board's standard is that a valid physician-patient relationship must exist and that prescribing decisions must meet the standard of care [7].

The FDA has issued at least two public warning letters to telehealth companies for marketing unapproved peptide therapies, signaling active enforcement interest in this space [8].